barzolvolimab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prurigo Nodularis
Conditions
Prurigo Nodularis
Trial Timeline
Apr 12, 2024 → Mar 1, 2027
NCT ID
NCT06366750About barzolvolimab
barzolvolimab is a phase 2 stage product being developed by Celldex Therapeutics for Prurigo Nodularis. The current trial status is active. This product is registered under clinical trial identifier NCT06366750. Target conditions include Prurigo Nodularis.
What happened to similar drugs?
1 of 7 similar drugs in Prurigo Nodularis were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07256392 | Phase 3 | Recruiting |
| NCT06366750 | Phase 2 | Active |
Competing Products
20 competing products in Prurigo Nodularis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| Upadacitinib | AbbVie | Approved | 50 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 35 |
| Rocatinlimab + Placebo | Amgen | Phase 3 | 44 |
| Abrocitinib | Pfizer | Phase 2 | 35 |
| Dupilumab SAR231893 (REGN668) | Sanofi | Pre-clinical | 33 |
| Dupilumab | Sanofi | Phase 3 | 47 |
| Dupilumab | Sanofi | Pre-clinical | 33 |
| Dupilumab | Sanofi | Pre-clinical | 30 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 26 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 37 |
| INCB054707 + Placebo | Incyte | Phase 2 | 32 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 44 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 44 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 37 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 23 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 32 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 32 |
| Nalbuphine ER Tablets + Placebo Tablets | Trevi Therapeutics | Phase 2/3 | 32 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 25 |